In vitro quantitative and relative gene expression analysis of pancreatic transcription factors Pdx-1, Ngn-3, Isl-1, Pax-4, Pax-6 and Nkx-6.1 in trans-differentiated human hepatic progenitors

Sandeep Kumar Vishwakarma1, Syed Rahamathulla1, Avinash Bardia1, Santosh K Tiwari1, Gunda Srinivas2, Avinash Raj2, Chaturvedula Tripura2, Annamaneni Sandhya3, Mohammed Aejaz Habeeb1, Aleem A Khan1*, Gopal Pande2, K Pratap Reddy4, P Yugandhar Reddy5

1Center for Liver Research and Diagnostics (CLRD), Deccan College of Medical Sciences, Kanchanbagh, 2Center for Cellular and Molecular Biology (CCMB), and 3Department of Genetics, Osmania University, 4Department of Zoology, Osmania University, Hyderabad, Andhra Pradesh, 5Department of Zoology, The Adony Arts and Science College, Kurnool, India

Keywords
Pancreatic transcription factors, Relative quantification, Trans-differentiation

*Correspondence
Aleem A Khan
Tel.: +91-40-24342954
Fax: +91-40-24342954
E-mail address: aleem_a_khan@rediffmail.com

J Diabetes Invest 2014; 5: 492–500
doi: 10.1111/jdi.12193

INTRODUCTION
In the past few years, islet transplantation has been used for the treatment of diabetes mellitus, but the limited yield of quality donor pancreata makes this strategy inadequate5. Therefore, patients affected by diabetes mellitus are in great need of the new source of cells to enable a better transition into clinical programs of cell therapy and regenerative medicine. β-Cells reside within the pancreatic islets, and are the only cell type in
mammals that synthesize and secrete the endocrine hormone, insulin. Insulin has a significant role in the regulation of carbohydrate, fat and protein metabolisms. Loss or dysfunction of β-cells results in an insufficient insulin production that leads to a high glucose level in the blood, ensuing a metabolic disorder called diabetes mellitus. This metabolic disorder is increasing in prevalence rate day-by-day throughout the world. It has been estimated that between 2010 and 2030, there will be a 69% increase in the number of patients with diabetes in developing countries, and a 20% increase in developed countries1,21.

The pancreas is a dual-function organ composed of various types of endocrine and exocrine cells. Among different types of pancreatic cells, the insulin-producing β-cell is of the most interest because of its close physiological connection to diabetes. Although both type I and type II diabetes can be effectively treated by insulin administration, the best way to cure diabetes is to restore the β-cell population. Unlike hepatocytes that have stem cell-like regenerative capability, the adult β-cells have very limited regenerative ability, which is insufficient to compensate the cell loss in diabetes. Pancreatic exocrine cells and endocrine β-cells have closely related lineages in development, and are derived from common progenitors. Conversion between them might require fewer epigenetic changes, thus representing an appealing source of β-cell regeneration. In this setting, the liver is becoming the most promising and available source of such cells because of its common origin with the ventral pancreas during embryonic development5. The knowledge of adult stem cells has added a new dimension to the study of the early events of liver development. Hepatic progenitors can be defined as the bipotential cells residing in human and animal livers, which have the ability to differentiate into a lineage of hepatocytes and cholangiocytes. Hepatic progenitors serve as the major component of the hepatic parenchyma in the early stages of liver organogenesis6. Epithelial cell adhesion molecule (EpCAM) is a transmembrane glycoprotein mediating Ca2+ independent homotypic cell–cell adhesion in epithelia, and is involved in cell signaling, migration, proliferation, and differentiation5,6. EpCAM has also been identified as a surface marker on human hepatic stem/progenitor cells that is absent on mature hepatocytes7,8, and can be isolated using EpCAM as a phenotypic marker. Trans-differentiation is defined as the conversion of one differentiated cell type to another. The process of trans-differentiation is essential to study, because it helps to intensify our understanding of the developmental biology of tissues that interconvert. Tissues that undergo trans-differentiation generally arise from adjacent regions in the developing embryo10. In normal development, the expression of one or more transcription factors encoded by the ‘master-switch’ gene is responsible for distinguishing the adjacent tissue type. Although different sets of transcription factors and specialized gene cascades are expressed in the liver and pancreas that generate specialized cell type after induction. Pdx-1 has been a major switch in order to control the activation of other transcription factors of different cell lineages11,12. Therefore, identifying gene expression profiles and their expression levels is the fundamental element for the biological inquiry at the cellular level to further investigate its potential and application in regenerative medicine. Techniques such as northern blot have been in existence for decades to carry out this task, but advances in molecular biology and bio-instrumentation have led to the development of a variety of new techniques with a wide range of sensitivities, throughputs and quantitative capabilities. The present study focused on the latter issue. For several commonly used gene expression techniques, the extent and range of quantitative applicability were used, and approaches for maximizing the accuracy and precision of these measurements were done.

The identification of a particular cell type involves an important aspect of the configuration of active and regulatory genes for the specific differentiation product in a stable manner. There are several transcription factors involved in both neogenesis and the replication of pancreatic β-cells (Table 1). However, it is not clear whether they work alone or in combination with other transcription factors. Therefore, it becomes crucial to have a better understanding of the various molecular pathways involved in pancreatic islet cell rejuvenation.

**Materials and Methods**

**Hepatocytes Isolation**

After receiving the informed consent from the parents, 12–20 weeks’ gestation aged human fetuses were obtained from the local maternity hospitals as a result of spontaneous abortion. Liver cells were isolated by a two-step collagenase digestion method described by Habibullah et al.13 Briefly, liver tissue was dissociated by two-step collagenase (0.3%) digestion at 37°C for 1 h, and filtered through a 40-µm nylon mesh to obtain single cell suspension. The study protocol was approved by the Institutional Ethics Committee, Deccan College of Medical Sciences, Hyderabad, India.

**Table 1 | Major transcription factors involved in pancreatic neogenesis**

| Gene | Function | Reference |
|------|----------|-----------|
| Pdx-1 | Initiate endocrine neogenesis | 15 |
| Ngn-3 | Initiate endocrine differentiation and activates NeuroD1 | 1 |
| Isl-1 | Essential for promoting pancreatic islets proliferation and maintaining endocrine cells survival in embryonic and postnatal pancreatic islets | 2 |
| Pax-4 | Expressed in endocrine progenitor cells, and directs formation of β- and δ-cells | 16 |
| Pax-6 | Pax6 acts upstream of MafB, which in turn might trigger the expression of insulin and regulate the PDX-1 and MafA expression required for β-cell maturation | 17 |
| Nkx-6.1 | Maintenance and expanding population of β-cell precursors as these progress from precursors to differentiated β-cells | 18 |
Cell Sorting
Enrichment of hepatic stem/progenitor cells was carried out by magnetic activated cell sorting (MACS) using human direct anti-EpCAM magnetic beads according to the manufacturer's instructions (MiltenyiBiotec, Bergisch Gladbach, Germany). Briefly, single cell suspension of enzymatically dissociated cells was first incubated with 60 μL EpCAM antibody for 30 min at 4°C. Cells were washed twice with 1X phosphate buffer saline (PBS; Invitrogen, Carlsbad, CA, USA) and then treated with magnetic microbeads (MiltenyiBiotec) for 15 min at 4°C. The magnetically labeled cells were applied onto a MS column (MiltenyiBiotec) followed by washing. After the suspension had gone through the column, the cells were washed three times using DMEM-F12 (Invitrogen), and the total effluent was collected as an unlabeled negative fraction (EpCAM-ve). The MS column was removed from the magnet and medium was applied onto the column. The retained magnetically labeled cells were gently flushed out by a plunger and collected as EpCAM+ve cells fraction.

Cell Viability Assays
Cell viability of EpCAM+ve cells was assessed by 0.2% Trypan-blue exclusion and fluorescein di-acetate (FDA) assays. Cell viability counting and enumeration was carried out using a hemocytometer.

In Vitro Proliferation of EpCAM+ve Cells
Enriched EpCAM+ve hHPCs cells (5 × 10^4) were cultured on collagen coated six-well plates in serum-free medium containing 20 ng/mL epidermal growth factor (EGF; PrepoTech, Londo, UK), 10 ng/mL basic fibroblast growth factor (b-FGF; PrepoTech), 20 ng/mL hepatocyte growth factor (HGF; Sigma, St. Louis, MO, USA), and 0.61 g/L nicotinamide (Sigma) with antibiotics and antimycotics. The 50% medium was replaced every after third day and cultured for 7 days.

Maturation of hHPCs
After proliferation for 7 days in serum-free medium, hepatic progenitors were induced to differentiate into mature hepatocyte lineage cells using DMEM-F12 (Sigma) supplemented with 20 ng/mL oncostatin M (Sigma), 1 μmol/L dexamethasone (Sigma) and 50 ng/mL insulin–transferrin–selenium premix (Sigma) for 15 days. The medium was changed twice a week, and differentiation was assessed by reverse transcriptase polymerase chain reaction (RT–PCR) for pancreatic β-cell transcription factors. All the experiments were repeated at least three times to eliminate any technical error.

Trans-Differentiation of Cultured EpCAM+ve hHPCs
Cultured EpCAM+ve hHPCs were harvested after 7 days of initial proliferation in serum-free medium and subcultured in six-well plates in conditioned medium containing antibiotics and antimycotics. The cells were induced with 5–30 mmol/L glucose concentration and maintained for 30 h at 37°C in a humidified atmosphere of 5%CO₂. After 2 h of post-induction, culture supernatants were collected every 4 h interval for 30 h, and the total insulin content secreted by the cells was estimated by chemiluminescence assay according to the manufacturer’s instructions (Auto Bio Labtech, Zhengzhou, China). The insulin production was highest (1 mU/L) in 23 mmol/L-induced glucose concentration and was lowest in 5 mmol/L glucose concentration after 24 h of incubation. These two cell sources were considered to correlate with the changes in relative gene expression profile of pancreatic transcription factors Pdx-1, Ngn-3, Isl-1, Pax-4, Pax-6 and Nkx-6.1 involved in β-cell production.

Immunocytochemical Staining
Cultured hHPCs and trans-differentiated cells were harvested by trypsinization and permeabilized with 0.1% Triton X-100 for 30 min at room temperature. Cells were incubated at 4°C for 2 h with mouse anti-human Pdx-1-PE (1:100 in PBS; R&D System, Delhi, India) and anti-human insulin-FITC (1:100 in PBS; R&D System, India) separately. After incubation cells were washed twice with cold 1X PBS and analyzed by inverted fluorescent microscopy (Axiovert; CarlZeiss, Gottingen, Germany). 4’,6-Diamidino-2-phenylindole, dihydrochloride (Sigma) was used as a counter dye to stain the cell nuclei.

Flow Cytometry
The 5 mmol/L and 23 mmol/L-induced hHPCs were permeabilized with 0.1% Triton X-100 (v/v) at room temperature for 15 min and stained with mouse anti-human Pdx-1 monoclonal antibody (1:100; R&D Systems, Minneapolis, MN, USA) at 4°C in the dark. PE-conjugated mouse immunoglobulin IgG1 was used as an isotype control. The expression was analyzed on FACS Caliber flow-cytometry using CellQuest software (BD Biosciences, San Jose, CA, USA).

Ribonucleic Acid Isolation and RT–PCR
Total ribonucleic acid (RNA) was extracted from uninduced, 5 mmol/L and 23 mmol/L-induced and pancreatic cells using the Trizol (Invitrogen) method. Complementary deoxyribonucleic acid (cDNA) was prepared using Oligo dT (Invitrogen) and reverse transcriptase II (Fermentas, Burlington, ON, Canada). Then, 5 ng of cDNA was used for reverse transcription quantitative polymerase chain reaction (RT–qPCR) analysis using SYBR chemistry in StepOne Real-Time PCR (Applied Biosystems, Carlsbad, CA, USA). Pancreatic transcription factors were amplified for 40 cycles using primers specific for Pdx-1, Ngn-3, Isl-1, Pax-4, Pax-6 and Nkx-6.1 gene transcripts. Primer pairs used in the study are listed in Table 2.

Relative Quantification
Fold changes in gene expression for pancreatic transcription factors in induced hHPCs were evaluated using relative quantification in reference to pancreatic cells. Glyceraldehyde
3-phosphate dehydrogenase (GAPDH) was used as endogenous control for normalization of the test samples. Before quantifying the test samples, cDNA from each sample was validated by GAPDH qPCR using 100, 10, 5, 2 and 0.1 ng as templates. Each transcript was amplified in triplicates. PCR efficiency was calculated using \( Y = mx + c \). The mean was taken for each sample and the fold difference was calculated using the \( 2^{-\Delta\Delta CT} \) method by StepOne (version 2.2) software in StepOne Real-Time PCR (Applied Biosystems).

**Table 2 | Primer details used for the relative quantification of pancreatic transcription factors**

| Target gene | Primer sequences (5’ to >3’) | Product size | GenBank # |
|-------------|------------------------------|--------------|-----------|
| Pdx-1       | FP- CCCATGAGTGAAGTCTACC      | 262 bp       | NM_000209 |
|             | RP- GTCTCTCTCTCTTTTCCAC      |              |           |
| Ngn-3       | FP- AAGACGGAGTGGCAGTCGAGC    | 229 bp       | NM_020999 |
|             | RP- GTGACAAGCTGTGGTCGCCG     |              |           |
| Isl-1       | FP- AGAGAGTCAGGTCAAGGTCTGGTT| 233 bp       | NM_006168 |
|             | RP- ACATCTGCTCTCTACAGCTGCG   |              |           |
| Pax-4       | FP- ATACCCGCCAGCAGATTTG      | 127 bp       | NM_006193 |
|             | RP- AAGACACTGTGCAGGTATGA     |              |           |
| Pax-6       | FP- TCACGACAGTGCACCAAACTGAC | 239 bp       | NM_000280 |
|             | RP- ATCATAACTCCGCACCTACCCG   |              |           |
| Nkx-6.1     | FP- AGAGAGTCAGGTCAAGGTCTGGT | 215 bp       | NM_006168 |
|             | RP- ACTTGTGCTTCTACAGCTGCG    |              |           |
| GAPDH       | FP- TGTGGGCCATCAAGGTGATTTGG  | 116 bp       | NM_014364 |
|             | RP- ACACCATGATTCGCCGGTCAAT   |              |           |

GAPDH, glyceraldehyde 3-phosphate dehydrogenase.

**Statistical Analysis**

All data were expressed as mean ± standard error of the mean. An independent-sample t-test (SPSS 10.0; SPSS Inc., Chicago, IL, USA) was used to compare the purity and viability of EpCAM+ve cells. Microsoft Excel was used to generate the graphical representation of EpCAM+ve cells quantitative yield and cell viability. \( P < 0.05\% \) was considered to be significant. RT–qPCR efficiency was calculated with the help of StepOne (version 2.2) software. A regression value \( (R^2) \geq 0.99 \) was considered to be the significant with 100% PCR efficiency.

**RESULTS**

**Isolation of Primary Hepatocytes From Human Fetal Liver**

Isolation of fetal hepatocytes by a two-step collagenase digestion method resulted in the utmost cell viability (95.2 ± 6.5%). The cells were morphologically normal, as assessed by confocal microscopy, with maintenance of gap junctions between cells and limited vacuolation. After MACS, EpCAM+ve cells were found to be homogeneous in nature with highest viability (>95%), whereas EpCAM-ve cells were heterogeneous in nature with less viability (90–92%). The average percentage of EpCAM+ve cells after MACS was calculated to be ~60–80%.

**In Vitro Proliferation and Characterization of EpCAM+ve Cells**

Magnetically sorted (EpCAM+ve) cells were maintained in culture for 7 days and did not show any morphological changes in proliferation medium. After induction with different concentrations of glucose, slight morphological changes were observed after 10 h. After 24 h of induction, cells completely changed in their morphology and started to secrete insulin that was further observed by immunocytochemical (ICC) staining.

**Flow Cytometry Analysis**

Flow cytometry data showed high expression for Pdx-1 in 23 mmol/L-induced cells after 24 h. More than 80% of 23 mmol/L-induced cells showed positive expression for Pdx-1, whereas a much smaller percentage of 5 mmol/L-induced cells were found to be positive, and no significant expression was observed in uninduced EpCAM+ve cells (Figure 2).

**Glucose-Induced Insulin Secretion by Cultured hHPCs**

Insulin estimation was carried out in 5–23 mmol/L-induced cells at 0–32 h. Insulin content measured the highest in 23 mmol/L-induced cells at 24 h of induction by chemifluorescence assay (Figure 3a,b). Further identification of insulin-producing cells was carried out by staining with anti-human insulin-FITC antibody. A high expression level was observed in trans-differentiated cells after 24 h of glucose induction. The expression pattern of insulin production was found to be similar to the pancreatic β-cells (Figure 4).

**Relative Gene Expression in Induced Hepatic Progenitors**

For gene expression analysis, samples were categorized in four groups: uninduced hHPCs (negative control), 5 mmol/L-induced cells, 23 mmol/L-induced cells and pancreatic cells (positive/reference control). Pdx-1, Ngn-3, Isl-1, Pax-4, Pax-6 and Nkx-6.1 transcription factors primarily involved in insulin secretion were examined in vitro by RT–qPCR. None of these transcription factors were expressed in uninduced hHPCs, except a minimal expression of Pdx-1. Although, their expression was slightly enhanced in 5 mmol/L-induced cells, and 23 mmol/L-induced cells have shown significantly increased expression (similar to the pancreatic cells).

The results obtained from the validation of cDNA for test and control samples showed constant expression levels for all target gene transcripts. The 5 ng cDNA resulted in better PCR efficiency and even curve for all the transcripts. Relative
Figure 1 | Immunocytochemical (ICC) staining with Pdx-1-PE antibody for 23 mmol/L-induced human hepatic progenitor cells after 24 h glucose induction (magnification, ×100). (a) High nuclear content was stained with 4′,6-diamidino-2-phenylindole, dihydrochloride (DAPI; blue). (b) Intracellular staining was observed for Pdx-1 (red). (c) Merged ICC image showing the nuclear staining for DAPI (blue) and cytoplasmic content for Pdx-1 (red).

Figure 2 | (a) Flow cytometry analysis of Pdx-1 expression in cultured uninduced hHPCs. (b) Only 9.88% cells showed positive expression for Pdx-1 after 5 mmol/L glucose induction. (c) More than 93% cells showed positive expression for Pdx-1 after 23 mmol/L glucose induction.
Quantification based on the $2^{-\Delta \Delta C_{t}}$ method showed that the human EpCAM+ve HPCs, when induced with 23 mmol/L glucose after 24 h, significantly increased the gene expression levels for all the pancreatic transcription factors in comparison with uninduced and 5 mmol/L-induced cells. While comparing the fold difference between the 23 mmol/L-induced hHPCs after 24 h and pancreatic cells, very less fold difference was observed between them (two-tailed $P = 0.0206$; Figure 5a,b).

**DISCUSSION**

Patients affected by diabetes mellitus are in great need of better therapeutic strategies and new source of cells to enable a better transition into clinical programs of cell therapy and regenerative medicine. In this setting, liver is becoming the most promising source of cells as it has the same embryonic origin as the pancreas. Stem cell biology is making waves around the globe with great anticipation for eventual diabetes therapy. Current work on hHPCs has offered new hope for the development of cell replacement therapy for diabetes. It has been proved that hHPCs constitute an average of 2% of the parenchyma of fetal liver, and can be isolated and enriched by EpCAM as potential phenotypic markers.

Figure 3 | Insulin estimation in cultured epithelial cell adhesion molecule-positive human hepatic progenitor cells. (a) Maximum insulin secretion was observed at 23 mmol/L glucose concentration after 24 h of the induction period. (b) Insulin production was found to be a maximum after 24 h of induction, which later gradually decreased (error bars are represented as 5% value).

Figure 4 | Immunocytochemical staining of cells using anti-human insulin-FITC. (a) Uninduced epithelial cell adhesion molecule-positive sorted human hepatic progenitor cells did not show expression for insulin. (b) High expression was observed in 23 mmol/L-induced cells after 24 h. (c) Pancreatic cells were used as a positive control to examine the expression pattern for insulin secretion from β-cells.
As the liver and pancreas arise from the same bipotential precursors in the anterior endoderm, it is reasonable to speculate that two closely related tissues might be interconvertible. Several animal studies have shown that Pdx-1 expression could lead to the conversion of hepatocytes into pancreatic β-like cells that secret insulin\textsuperscript{12,13}. Likewise, it has also been found that the combination of Pdx-1 and Ngn-3 could synergistically induce expression of β-cell factors and insulin biosynthesis in the liver, and drastically ameliorate glucose tolerance\textsuperscript{14}. Taken together, these studies showed that liver and pancreatic cells might possess the plasticity of converting into each other under certain circumstances. Though many of these studies might not make an instant breakthrough in the clinic, they contribute enormously to our understanding of cell lineage determination and therefore could eventually lead to the success of cell therapies. In this scenario, the present study strongly suggests that culture
of EpCAM+ve-enriched hHPCs possesses the capacity to transdifferentiate into functional endocrine pancreatic β-cells after 24 h of 23 mmol/L glucose induction. RT–qPCR analysis of major pancreatic transcription factors in induced cells has shown the increased expression of their messenger RNA transcripts. Interestingly, a significant increase in expression level of Nkx-6.1 almost equal to Pdx-1 shows a more committed β-cell phenotype for insulin production. An endocrine pancreatic β-cell phenotype was further supported by ICC staining of Pdx-1 and chemiluminescence assay, which showed the presence of insulin-producing cells and insulin content, respectively, in trans-differentiated cells.

Characterization of Pdx-1 in induced hHPCs is of utmost importance, as it activates expression of other islet-enriched genes. Several studies have shown Pdx-1 as a ‘master regulator’ of directing cell fate towards the pancreatic endocrine cells19,20. In the present study, after 23 mmol/L glucose induction, >80% of cells were found to express Pdx-1, which later activates other transcription factors and shows the potential to generate pancreatic β-cells. Relative quantification of Pdx-1, Ngn-3, Isl-1, Pax-4, Pax-6 and Nkx-6.1 genes showed a significantly high expression level in trans-differentiated cells and defined the parameters to achieve the desired β-cell population.

Furthermore, with the increasing rate of diabetes patients throughout the world, it is necessary to have a new approach for the development of suitable therapies21 and diagnosis. Confirmation of chronic hyperglycemia is essential for the diagnosis of diabetes mellitus. In 1999, the Japan Diabetes Society (JDS) introduced a new parameter (glycated hemoglobin [HbA1c]) for better diagnosis of the diabetic condition22. Later, the value of HbA1c was defined in different diabetic conditions, and it was shown that ≥6.5% HbA1c can be considered to indicate the diabetic type. The value of HbA1c is equivalent to the internationally used HbA1c (%) (HbA1c [NGSP]) defined by the National Glycohemoglobin Standardization Program (NGSP), and is expressed by adding 0.4% to the HbA1c (JDS) (%) defined by the JDS23.

In this scenario, the present study with the molecular and cellular biology aspect provides the continual promise of exciting new insights into β-cell development and survival. In summary, the present study has shown a potential approach in cell therapy-based treatment of insulin-dependent diabetes by generating insulin-producing cells from induced hHPCs. While foreseeing immense potentials of these discoveries, certain issues remain to be addressed within the coming years, such as the efficiency of the cell trans-differentiation, the maturation of the hepatocytes or β-cells, and the elimination of any possible tumor-initiating cells resulting from incomplete epigenetic conversion. Once we achieve a comprehensive understanding of the mystery behind hHPCs trans-differentiation, we might be able to use the knowledge of refined and controlled production of β-cells from alternative sources to move further from bench to bedside for the treatment of diabetes mellitus.

REFERENCES

1. Gasa R, Mrejen C, Lynn FC, et al. Induction of pancreatic islet cell differentiation by the neurogenin-neuroD cascade. Differentiation 2008; 76: 381–391.

2. Guo T, Wang W, Zhang H, et al. ISL1 promotes pancreatic islet cell proliferation. PLoS ONE 2011; 6: e22387.

3. Habibullah CM, Syed IH, Qamar A, et al. Human fetal hepatocyte transplantation in patients with fulminant hepatic failure. Transplantation 1994; 58: 951–952.

4. Zaret KS. Genetic programming of liver and pancreas progenitors: lessons for stem-cell differentiation. Nat Rev Genet 2008; 9: 329–340.

5. Maetzel D, Denzel S, Mack B, et al. Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol 2009; 11: 162–171.

6. Osta WA, Ziaei M, Mikitarian K, et al. EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res 2004; 64: 5818–5824.

7. Zhang L, Theise N, Chua M, et al. The stem cell niche of human livers: symmetry between development and regeneration. Hepatology 2008; 48: 1598–1607.

8. De Boer CJ, van Krieken JH, Janssen-van Rhijn CM, et al. Expression of Ep-CAM in normal, regenerating, metaplastic, and neoplastic liver. J Pathol 1999; 188: 201–206.

9. Schmelzer E, Wauthier E, Reid LM. The phenotypes of pluripotent human hepatic progenitors. Stem Cells 2006; 24: 1852–1858.

10. Slack JM, Tosh D. Transdifferentiation and metaplasia–switching cell types. Curr Opin Genet Dev 2001; 11: 581–586.

11. Schmelzer E, Zhang L, Bruce A, et al. Human hepatic stem cells from fetal and postnatal donors. J Exp Med 2007; 204: 8.

12. Ferber S, Halkin A, Cohen H, et al. Pancreatic and duodenal homeobox gene 1 induces expression of insulin genes in liver and ameliorates streptozotocin-induced hyperglycemia. Nat Med 2000; 6: 568–572.

13. Aviv V, Melvar-Levy I, Rachmut IH, et al. Exendin-4 promotes liver cell proliferation and enhances PDX-1-induced liver to pancreas transdifferentiation. J Biol Chem 2009; 284: 33509–33520.

14. Yechoor V, Liu V, Espiritu C, et al. Neurogenin 3 is sufficient for transdetermination of hepatic progenitor cells into neoislets in vivo but not transdifferentiation of hepatocytes. Dev Cell 2009; 16: 358–373.

15. Taniguchi H, Yamato E, Tashiro F, et al. β-cell neogenesis induced by adenovirus-mediated gene delivery of transcription factor pdx-1 into mouse pancreas. Gene Ther 2003; 10: 15–23.

16. Sosa-Pineda B, Chowdry K, Torres M, et al. The Pax-4 gene is essential for differentiation of insulin-producing β-cells in mammalian pancreas. Nature 1997; 386: 399–402.
17. Nishimura W, Kondo T, Salameh T, et al. A switch from MafB to MafA expression accompanies differentiation to pancreatic β-cells. Dev Biol 2006; 293: 526–539.

18. Sander M, Sussel L, Conners J, et al. Homeobox gene Nkx6.1 lies downstream of Nkx2.2 in the major pathway of β-cell formation in the pancreas. Development 2000; 127: 5533–5540.

19. Ber I, Shternhall K, Perl S, et al. Functional, persistent, and extended liver to pancreas transdifferentiation. J Biol Chem 2003; 278: 31950–31957.

20. Kojima H, Fujimya M, Matsumura K, et al. NeuroDβ-cellulin gene therapy induces islet neogenesis in the liver and reverses diabetes in mice. Nat Med 2003; 9: 596–603.

21. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; S87: 4–14.

22. Kashiwagi A, Kasuga M, Araki E, et al. International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values. J Diabetes Invest 2012; 3: 39–40.

23. Seino Y, Nanjo K, Tajima N, et al. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Invest 2010; 1: 212–228.